Essen/Paderborn, October 14, 2024 – Over 24,000 visitors came together in Munich from October 9 to 12, 2024 at expopharm 2024, the leading European trade fair for the pharmacy market. Over 500 exhibitors and 200 renowned speakers presented a wide range of innovations and specialist lectures at the event. Participants were able to find out about the latest developments, innovations and future-oriented trends in the pharmacy sector. One of the fastest growing segments is the medical cannabis sector. Against this background, many eyes were also on Four 20 Pharma GmbH (Four 20 Pharma), one of the leading German medical cannabis companies. The Paderborn-based company attracted attention not only with a modern exhibition stand, but also with a special accent in the supporting program.
For the first time, Four 20 Pharma held its own panel discussion, which underscores the company's role as an important player in this future market. This step marked a milestone for the company. On the second day of the trade fair, Four 20 Pharma presented the panel discussion " Medical cannabis: The long road from therapy to application - and the significance for patients " on the "pharma world" stage, moderated by the renowned physician Prof. Dr. mult. Eckhard Nagel.
The event, which was attended by Dr. med. Dipl.-Chem. Konrad F. Cimander, President of the German Medical Cannabis Society, Johannes Hoffmann, a pharmacist specializing in medicinal cannabis, and Michael Hagemeier, a member of the Four 20 patient advisory board, was very well received. With their diverse perspectives - from the medical to the pharmaceutical to the patient-related point of view - the participants offered valuable insight into the challenges, but also the opportunities, of therapy with the medicinal plant.
The protagonists emphasized, among other things, that medical cannabis is an effective option for many illnesses and the challenges one faces in raising awareness and convincing skeptics. Hagemeier, who suffers from multiple sclerosis, talked about his years-long odyssey through the healthcare system before he finally found his way to cannabis from the black market and then, since 2017, medical cannabis. He emphasized the need to reduce the bureaucratic hurdles to accessing this form of therapy in order to give patients like him a better quality of life. Cimander, who has been campaigning for the acceptance of medical cannabis for years, advocated for the plant to be more widely used as an alternative to opiates in the treatment of chronic pain and other illnesses. Hoffmann, who as a pharmacist is familiar with the practical aspects of medical cannabis use, emphasized the importance of professional advice and dosage to ensure safe and effective therapy.
"The response to our first panel discussion was overwhelming," said a delighted Alexander Gocke, Head of Sales at Four 20 Pharma, who also answered questions from the organizer Avoxa in an extensive interview. "It was great to see that interest in medicinal cannabis is increasing year after year - not only among patients and doctors, but also among pharmacists, who are increasingly recognizing the opportunities this opens up for them." After the discussion, visitors also had the opportunity to ask questions and talk directly with the experts. The lively discussions showed that the audience was not only interested in technical matters.
>>To the exhibitor interview with organizer Avoxa<<
Medical cannabis as a crowd puller
The lecture also attracted many trade fair visitors to the inviting stand of the Paderborn-based company, so Four 20 Pharma was also in demand away from the stage: The modern and eye-catching exhibition stand served as a meeting point for trade visitors throughout the event, who were able to find out about the company's high-quality medicinal cannabis products - from flowers to the extracts of the Adven brand. The quality and therapeutic effectiveness of the products in particular attracted great interest. From pharmacists and doctors to industry colleagues and media representatives, interest in the topic of medicinal cannabis was noticeably greater than in previous years - which certainly also had something to do with the partial legalization of cannabis in April 2024.
Gocke adds: "The intensive discussions we had at the stand were once again incredibly valuable. We not only spoke with pharmacists and doctors about specific applications, but also with potential partners from various areas of the industry and with media representatives. These productive dialogues showed us that medicinal cannabis is increasingly gaining a foothold in the healthcare sector." The positive atmosphere during four exhausting and intensive days of the trade fair was particularly nice.
Thomas Schatton, founder and CEO of Four 20 Pharma, also draws a positive conclusion from the trade fair: "Our tireless educational work is bearing more and more fruit and we can clearly see that the reservations about medicinal cannabis are being reduced step by step. We are delighted that more and more people are recognizing the benefits of this medicinal plant. Of course, we have not yet reached our goal, but we are making progress - and the increasing openness motivates us to continue. The four days at expopharm can definitely be considered a complete success for us."
In addition, Four 20 Pharma took the opportunity to announce the launch of the new brand “Huala”, aimed at patients seeking high-quality medicinal cannabis flowers at moderate prices. With this expansion, Four 20 Pharma is responding to the increasing demand for affordable medicinal cannabis options.
https://www.mynewsdesk.com/de/420pharma/pressreleases/von-der-buehne-zum-stand-four-20-pharma-zieht-auf-der-expopharm-grosses-interesse-auf-sich-3348606